Merck And AiCuris Report Phase 2 Results Of Antiviral Letermovir

AiCuris and Merck announced positive results from the Phase II trial of the investigational antiviral agent letermovir in bone marrow transplant patients.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news